UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 ______________

 

FORM 8-K

 

CURRENT REPORT

 

PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934

 

Date of Report (Date of earliest event reported): August 24, 2015

 

Titan Pharmaceuticals, Inc.

 

(Exact Name of Registrant as Specified in Charter)

 

Delaware

0-27436 

94-3171940 

(State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.)

 

 

400 Oyster Point Blvd., Suite 505, South San Francisco, CA 

94080 

(Address of Principal Executive Offices) (Zip Code)

  

Registrant’s telephone number, including area code: 650-244-4990

 

 

 

 (Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 

 

Item 5.07. Submission of Matters to a Vote of Security Holders.

 

On August 24, 2015, Titan Pharmaceuticals, Inc. (the “Company” or “Titan”) held its annual meeting of stockholders. The following matters were considered:

 

  1. Election of Directors

 

Stockholders elected all of the Company’s nominees for director for one-year terms expiring on the next annual meeting of stockholders. The voting results were as follows:

 

   FOR   AGAINST   BROKER NON-VOTE 
Joseph A. Akers   40,817,347    1,751,051    50,614,501 
Victor J. Bauer   40,837,286    1,731,112    50,614,501 
Sunil Bhonsle   39,367,907    3,200,491    50,614,501 
Eurelio M. Cavalier   40,808,562    1,759,836    50,614,501 
M. David MacFarlane   40,829,079    1,739,319    50,614,501 
James McNab, Jr.   40,831,802    1,736,596    50,614,501 
Marc Rubin   40,358,822    2,209,576    50,614,501 
Ley S. Smith   40,816,579    1,751,819    50,614,501 

 

2.Adoption of the 2015 Omnibus Incentive Plan

 

Stockholders approved the Titan Pharmaceuticals, Inc. 2015 Omnibus Equity Incentive Plan pursuant to which 7,500,000 shares of common stock have been reserved for issuance as or under awards. The voting results were as follows:

 

FOR   AGAINST   ABSTAIN   BROKER NON-VOTES 
 33,819,511    5,586,212    3,162,675    50,614,501 

 

3.Approval of the Reverse Split

 

Stockholders approved an amendment to the Company’s certificate of incorporation to effect a reverse split of the common stock within a range of one-for-three and one-for-eight, with the exact ratio to be determined by the board of directors at the appropriate time. The voting results were as follows:

 

FOR   AGAINST   ABSTAIN 
 66,876,118    25,404,267    902,514 

 

4.Approval and Ratification of Auditors

 

Stockholders approved and ratified the reappointment of OUM & Co. LLP to serve as the Company’s independent auditors for the fiscal year ending December 31, 2015. The voting results were as follows:

 

FOR   AGAINST   ABSTAIN 
 87,391,719    3,298,470    2,492,710 

 

 

 

  

5.Approval of Executive Compensation

 

Stockholders approved the compensation of the Company’s executive officers. The voting results were as follows:

 

FOR   AGAINST   ABSTAIN   BROKER NON-VOTES 
 33,220,475    6,526,641    2,821,282    50,614.501 

 

6.Frequency of Say-on-Pay

 

Stockholders adopted a resolution stating that an advisory vote to approve executive compensation (“say-on-pay”) be submitted to stockholders every two years. The voting results were as follows:

 

ONE YEAR   TWO YEARS   THREE YEARS   ABSTAIN  

BROKER NON-VOTES

 
 5,672,970    32,602,863    671,737    3,620,828    50,614,501 

 

In light of the voting results with respect to the frequency of say-on-pay, Titan’s board of directors has determined that say-on-pay votes should be held every two years.

 

Item 9.01. Financial Statements and Exhibits.

 

(d) Exhibits

 

Exhibit No. Description
   
10.31 Titan Pharmaceuticals, Inc. 2015 Omnibus Equity Incentive Plan

 

 

 

 
SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Dated:  August 25, 2015 TITAN PHARMACEUTICALS, INC.
   
  By: /s/ Sunil Bhonsle
  Name: Sunil Bhonsle
  Title: President

 

 

 

 

Exhibit Index

 

Exhibit No. Description
   
10.31 Titan Pharmaceuticals, Inc. 2015 Omnibus Equity Incentive Plan